Currently, prostate-specific antigen (PSA) and multiparametric magnetic resonance imaging (mpMRI) both play essential roles in PCa screening and the selection of suitable candidates for biopsy (2, 3). This evidence concerns the gene KLK3 and posterior cortical atrophy.